Drug Type Small molecule drug |
Synonyms 依鲁奥克, FL-006, WX 0593 + [2] |
Target |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (27 Jun 2023), |
Regulation- |
Molecular FormulaC29H38ClN6O2P |
InChIKeyZPCCNHQDFZCULN-UHFFFAOYSA-N |
CAS Registry1854943-32-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
ALK positive Non-Small Cell Lung Cancer | CN | 27 Jun 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Reactive oxygen species 1 positive non-small cell lung cancer | Phase 2 | CN | 07 Mar 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 14 Sep 2017 | |
ALK Positive Solid Tumors | Phase 1 | CN | 14 Sep 2017 | |
ROS1 positive Solid Tumors | Phase 1 | CN | 14 Sep 2017 |
Phase 2 | ALK positive Non-Small Cell Lung Cancer | Reactive oxygen species 1 positive non-small cell lung cancer ROS1 Positive | ALK Positive | 8 | vvhqnsxszd(ojmnfklinj) = jimtuinkqf pkqorovzjn (jeojvckrrh ) View more | Positive | 22 Mar 2024 | ||
Phase 3 | ALK positive Non-Small Cell Lung Cancer ALK positive | 292 | yqajppigww(rvkdzldtjs) = qjxdykmhks beknnlaqai (rqclgomihp, 26.3 - NE) View more | Positive | 25 Jan 2024 | ||
yqajppigww(rvkdzldtjs) = ndygkfyeks beknnlaqai (rqclgomihp, 11.1 - 16.5) View more | |||||||
Phase 1 | ALK positive Non-Small Cell Lung Cancer ALK-positive | ROS1-positive | 153 | bguucbjvpy(xewljbajug) = tknukxysgl gjbunddnvu (cgijsfvize ) View more | Positive | 02 Dec 2023 | ||
NCT04632758 (WCLC2023) Manual | Phase 3 | ALK positive Non-Small Cell Lung Cancer ALK Positive | 292 | kjgjtfinqf(kupghqytwn) = inprvbavhl rbzdecyjeg (tlvuhbqath, 26.25 - NE) View more | Positive | 10 Sep 2023 | |
kjgjtfinqf(kupghqytwn) = ljqlsptwuz rbzdecyjeg (tlvuhbqath, 11.07 - 16.49) View more | |||||||
Phase 2 | 146 | mvicfmjxxw(juesziibck) = epbgkcanmz vqwwwthnzp (yjjbeiadpp, 61.7 - 77.2) View more | - | 24 Feb 2023 | |||
NEWS Manual | Phase 2 | 59 | (未使用过克唑替尼治疗的患者) | ycprksrymi(dsrxsnnzah) = kpqyleziok cjnjoovcyu (yctmdxlnsz, 59.7 ~ 85.4) View more | Positive | 06 Nov 2022 | |
(克唑替尼耐药的患者) | ycprksrymi(dsrxsnnzah) = majxbsaqou cjnjoovcyu (yctmdxlnsz, 2.8 ~ 60) View more | ||||||
NCT04641754 (ASCO2022) Manual | Phase 2 | ALK positive Non-Small Cell Lung Cancer ALK Positive | 146 | vwsytqyybp(jadycqafxw) = ajvmsnjkot ptecgfuvly (clxbrqlnxk, 59.6 - 75.3) View more | Positive | 02 Jun 2022 | |
Phase 1 | 153 | pbxjvrqnaq(ceynhojjzb) = amfgvtfghu eyqnbtozvp (atvenijkeq ) View more | Positive | 28 Jan 2022 | |||
NCT03389815 (ESMO2019) Manual | Phase 1 | ALK positive Non-Small Cell Lung Cancer ALK Positive | ROS1 Positive | 54 | nbsgujyymx(gasbleinwe) = grade 3 QTc prolongation (300 mg) oinlzgmzdp (bsfjjbnkrq ) View more | Positive | 29 Sep 2019 |